Document Type : Original Article


1 Medical Biotechnology Institute, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran

2 Rasole Akram Hospital, Iran University of Medical Sciences, Tehran, Iran


Background: Cancer/testis antigens are a unique class of tumor antigens with normal expressions restricted to the testis and various cancers, but not in adult somatic tissues. Sperm-associated antigen 9 (SPAG9) has been introduced as a new member of Cancer Testis Antigens family involved in c-Jun-NH2-kinase signaling module. The objective of this research was to investigate the potential of SPAG9 as a diagnostic and prognostic biomarker in breast cancer. We further aimed to find any significant association between SPAG9 expression and clinicopathologic features of the cancer.
Methods: In this retrospective study, 35 breast cancer tissues and 35 adjacent non-cancerous tissues were collected and examined using RT-PCR to explore SPAG9 mRNA expression. Statistical analysis was done utilizing SPSS 22.0 software.
Results: Unexpectedly, we detected SPAG9 expression in 54% of adjacent non-cancerous tissues. Moreover, SPAG9 mRNA was expressed in 57% of cancerous tissues. Statistical analysis showed a significant association between SPAG9 expression and tumor size, lymph node metastasis, and cancer stage.
Conclusion: The association between the gene expression and tumor size, lymph, node and metastasis, and cancer stage suggests that SPAG9 can potentially be considered as a prognostic biomarker in breast cancer. However, it may not be a candidate diagnostic biomarker.


How to cite this article:

Naraghi H, Mahjoubi F, Nafissi N. Sperm-associated antigen 9 as a candidate diagnostic and prognostic biomarker in breast cancer. Middle East J Cancer. 2020;11(4): 415-22. doi: 10. 30476/mejc.2020.81553.102.

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86. doi: 10.1002/ijc.29210.
2.Haghighat S, Akbari ME, Yavari P, Javanbakht M, Ghaffari S. Cost-effectiveness of three rounds of mammography breast cancer screening in Iranian women. Iran J Cancer Prev. 2016;9(1):e5443. doi: 10.17795/ijcp-5443.
3.Otaghvar HA, Hosseini M, Tizmaghz A, Shabestanipour G, Noori H. A review on metastatic breast cancer in Iran. Asian Pac J Trop Biomed. 2015;5(6):429-33.
4.Rahimzadeh M, Pourhoseingholi MA, Kavehie B. Survival rates for breast cancer in Iranian patients: a meta- analysis. Asian Pac J Cancer Prev. 2016;17(4):2223-7.
5.Nicolini A, Ferrari P, Duffy MJ. Prognostic and predictive biomarkers in breast cancer: Past, present and future. Semin Cancer Biol. 2018;52(Pt1):56-73. doi: 10.1016/j.semcancer.2017.08.010.
6. Hofmann O, Caballero OL, Stevenson BJ, Chen YT, Cohen T, Chua R, et al. Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A. 2008;105(51):20422-7. doi: 10.1073/pnas.0810777105.
7. Garg M, Kanojia D, Khosla A, Dudha N, Sati S, Chaurasiya D, et al. Sperm-associated antigen 9 is associated with tumor growth, migration, and invasion in renal cell carcinoma. Cancer Res. 2008;68(20):8240-8. doi: 10.1158/0008-5472.CAN-08-1708.
8.Ren B, Zou G, He J, Huang Y, Ma G, Xu G, et al. Sperm-associated antigen 9 is upregulated in hepatocellular carcinoma tissue and enhances QGY cell proliferation and invasion in vitro. Oncol Lett. 2018;15(1):415-422. doi: 10.3892/ol.2017.7270.
9. Jagadish N, Fatima R, Sharma A, Devi S, Suri V, Kumar V, et al. Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma. Tumour Biol. 2018;40(5):1010428318773652. doi: 10.1177/1010428318773652.
10. Charan J, Biswas T. How to calculate sample size for different study designs in medical research? Indian J Psychol Med. 2013;35(2):121-6. doi: 10.4103/0253-7176.116232.
11. Kanojia D, Garg M, Gupta S, Gupta A, Suri A. Sperm-associated antigen 9 is a novel biomarker for colorectal cancer and is involved in tumor growth and tumorigenicity. Am J Pathol. 2011;178(3):1009-20. doi: 10.1016/j.ajpath.2010.11.047.
12. Zhang L, Yan L, Cao M, Zhang H, Li C, Bai Y, et al. SPAG9 promotes endometrial carcinoma cell invasion through regulation of genes related to the epithelial-mesenchymal transition. Eur J Gynaecol Oncol. 2016;37(3):312-9.
13. Ren B, Wei X, Zou G, He J, Xu G, Xu F, et al. Cancer testis antigen SPAG9 is a promising marker for the diagnosis and treatment of lung cancer. Oncol Rep. 2016;35(5):2599-605. doi: 10.3892/or.2016.4645.
14. Yang X, Zhou W, Liu S. SPAG9 controls the cell motility, invasion and angiogenesis of human osteosarcoma cells. Exp Ther Med. 2016;11(2):637-644.
15. Garg M, Kanojia D, Salhan S, Suri S, Gupta A, Lohiya NK, et al. Sperm-associated antigen 9 is a biomarker for early cervical carcinoma. Cancer. 2009;115(12):2671-83. doi: 10.1002/cncr.24293.
16. Kanojia D, Garg M, Gupta S, Gupta A, Suri A. Sperm-associated antigen 9, a novel biomarker for early detection of breast cancer. Cancer Epidemiol Biomarkers Prev. 2009;18(2):630-9. doi: 10.1158/1055-9965.EPI-08-0629.
17. Sinha A, Agarwal S, Parashar D, Verma A, Saini S, Jagadish N, et al. Down regulation of SPAG9 reduces growth and invasive potential of triple-negative breast cancer cells: possible implications in targeted therapy. J Exp Clin Cancer Res. 2013;32:69. doi: 10.1186/1756-9966-32-69.
18. Whitehurst AW. Cause and consequence of cancer/testis antigen activation in cancer. Annu Rev Pharmacol Toxicol. 2014;54:251-72. doi: 10.1146/annurev-pharmtox-011112-140326.
19.Aran D, Camarda R, Odegaard J, Paik H, Oskotsky B, Krings G, et al. Comprehensive analysis of normal adjacent to tumor transcriptomes. Nat Commun. 2017;8(1):1077. doi: 10.1038/s41467-017-01027-z.